No annual revenue total was found in Acrivon Therapeutics, Inc.'s SEC filings.
Acrivon Therapeutics, Inc. (ACRV) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$65.3 million. As of Jun 30, 2026 it held $90.0 million in cash and investments and $2.1 million in total debt.
Revenue
—
Net income (TTM)
$-74.22M
+13.6% vs year-ago TTM
Operating cash flow (TTM)
$-62.92M
+11.2% vs year-ago TTM
Free cash flow (TTM)
$-64.14M
+12.4% vs year-ago TTM
EPS (TTM)
$-1.88
+16.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
38.74M
+23.6% vs prior year
Net cash
$87.84M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRV (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1781174
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M |
| Diluted EPS | -$2.02 | -$2.38 | -$2.74 | -$7.56 |
| Operating cash flow | -$63.7M | -$65.7M | -$42.6M | -$30.1M |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M |
| Stockholders' equity | $112.5M | $176.8M | $121.2M | $170.5M |
| Cash and investments | $118.6M | $184.6M | $127.5M | $169.6M |
| Total debt | $2.7M | $3.6M | $4.6M | $5.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 346 Acrivon Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.